Unknown

Dataset Information

0

Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma.

ABSTRACT:

SUBMITTER: Vu K 

PROVIDER: S-EPMC8776513 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma.

Vu Khoan K   Mannis Gabriel G   Hwang Jimmy J   Geng Huimin H   Rubenstein James L JL  

British journal of haematology 20190203 1

Similar Datasets

Unknown Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma.
| S-EPMC12310512 | biostudies-literature
Unknown Primary central nervous system lymphoma in older adults and the rationale for maintenance strategies: a narrative review.
| S-EPMC8802984 | biostudies-literature
Unknown Hepatotoxicity from high-dose methotrexate in primary central nervous system lymphoma.
| S-EPMC10180358 | biostudies-literature
Unknown Primary central nervous system lymphoma.
| S-EPMC9437714 | biostudies-literature
Unknown Autoimmune conditions and primary central nervous system lymphoma risk among older adults.
| S-EPMC7012721 | biostudies-literature
Unknown Population pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma
| S-EPMC12127635 | biostudies-literature
Unknown A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma.
| S-EPMC10000886 | biostudies-literature
Unknown Risk factors associated with high-dose methotrexate induced toxicities in primary central nervous system lymphoma.
| S-EPMC12358356 | biostudies-literature
Unknown Relapsed Primary Central Nervous System Lymphoma: Current Advances.
| S-EPMC8118624 | biostudies-literature
Unknown Case-based review: primary central nervous system lymphoma.
| S-EPMC6656340 | biostudies-literature